The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

Sections

History and Discovery | Structure–Activity Relations | Pharmacological Profile | Pharmacokinetics and Disposition | Mechanism of Action | Indications and Efficacy | Side Effects and Toxicology | Drug–Drug Interactions | Conclusion | References

Excerpt

Research has implicated dysregulation of serotonin (5-hydroxytryptamine [5-HT]) in mood and anxiety disorders. Researchers therefore identified compounds that are selective in blocking neurotransmitter reuptake and yet have little agonist and antagonist activity at receptors thought to be associated with adverse effects. Sertraline, a naphthylamino compound that is structurally different from monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs), is a member of this class of drugs (Guthrie 1991; Heym and Koe 1988).

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.
  • Institutional Login
  • Sign in via OpenAthens
  • Register for access
  • Please login/register if you wish to pair your device and check access availability.

    Not a subscriber?

    Subscribe Now / Learn More

    PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

    Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).